12:00 AM
 | 
Feb 28, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Repel-CV: Pilot data

CHAI said that its 22-patient U.S. pilot clinical trial showed that Repel-CV was safe and well-tolerated compared to a standard...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >